Personalized post-surgical care?—possible strategies for NSCLCs with EGFR mutation

摘要

Personalized treatment has become the standard of care for advanced stage non-small-cell lung cancer (NSCLC) patients ( ). Mutational status of driver genes, such as epidermal growth factor receptor ( ), anaplastic lymphoma kinase ( ), and , as well as membranous protein expression of programmed death-ligand 1 (PD-L1) in tumor cells are used to select the appropriate systemic therapy for these patients. However, in earlier stage cases, NSCLCs are still being treated as one disease even though surgical resection provides large amounts of tumor tissue for molecular analyses.